Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 20;138(16):2040-2042.
doi: 10.1097/CM9.0000000000003593. Epub 2025 Jun 6.

Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study

Jingyi Li  1 , Yunsheng Liang  2 , Wenli Feng  3 , Liehua Deng  4 , Hong Fang  5 , Chao Ji  6 , Youkun Lin  7 , Furen Zhang  8 , Rushan Xia  9 , Chunlei Zhang  10 , Shuping Guo  11 , Mao Lin  12 , Yanling Li  13 , Shoumin Zhang  14 , Xiaojing Kang  15 , Liuqing Chen  16 , Zhiqiang Song  17 , Xu Yao  18 , Chengxin Li  19 , Xiuping Han  20 , Guoxiang Guo  21 , Qing Guo  22 , Xinsuo Duan  23 , Jie Li  24 , Juan Su  24 , Shanshan Li  25 , Qing Sun  26 , Juan Tao  27 , Yangfeng Ding  28 , Danqi Deng  29 , Fuqiu Li  30 , Haiyun Suo  31 , Shunquan Wu  31 , Jingbo Qiu  31 , Hongmei Luo  31 , Linfeng Li  32 , Ruoyu Li  33
Affiliations

Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study

Jingyi Li et al. Chin Med J (Engl). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

This study was supported by China Shijiazhuang Pharmaceutical Group Co., Ltd., China.

Figures

Figure 1
Figure 1
Treatment of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria. (A): The mean changes in ISS7 from baseline during the treatment period (FAS). (B): The mean changes in UAS7 from baseline during the treatment period (FAS). (C): The mean changes in NHS7 from baseline during the treatment period (FAS). (D): Forest plot for subgroups—Between-group differences in ISS7 change from baseline at week 12. CI: confidence interval; FAS: full analysis set; ISS7: weekly itch severity score; LS: least squares; NHS7: weekly number of hives score; SD: standard deviations, UAS7: weekly urticaria score.
See this image and copyright information in PMC

References

    1. Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers 2022;8:61. doi: 10.1038/s41572-022-00389-z. - PubMed
    1. Li J Mao D Liu S Liu P Tian J Xue C, et al. Epidemiology of urticaria in China: A population-based study. Chin Med J 2022;135:1369–1375. doi: 10.1097/cm9.0000000000002172.11. - PMC - PubMed
    1. Zuberbier T Abdul Latiff AH Abuzakouk M Aquilina S Asero R Baker D, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022;77:734–766. doi: 10.1111/all.15090. - PubMed
    1. FDA . XOLAIR® (omalizumab) label. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103976s5238lbl.... [Last accessed on 24 June, 2024].
    1. Zhao ZT Ji CM Yu WJ Meng L Hawro T Wei JF, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016;137:1742–1750.e1744. doi: 10.1016/j.jaci.2015.12.1342. - PubMed

LinkOut - more resources